Therapeutic Peptides for Diabetes Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly type 1 and type 2, face challenges such as weight gain, increased cancer risk, and hypoglycemia, necessitating the development of novel non-insulin compounds that can address insulin resistance and hyperglycemia while reducing associated complications.
Innovation Solution
Peptides with specific amino acid sequences, such as KX2LAX5X6X7X8LX10LX12YGIK and VDZ3Z4Z5GZ7Z8SZ10Z11YGLR, are developed to stimulate β-cell proliferation, protect against apoptosis, and enhance insulin secretion, thereby lowering plasma glucose levels and delaying the onset of diabetes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If insulin treatment is used to lower plasma glucose levels, then hyperglycemia is controlled, but weight gain and increased risks of cancer and hypoglycemia occur
Solution Approach 1:
The invention segments the diabetes treatment approach by developing peptide compounds with specific amino acid sequences (KX2LAX5X6X7X8LX10LX12YGIK and VDZ3Z4Z5GZ7Z8SZ10Z11YGLR) that act through different mechanisms than insulin, targeting β-cell proliferation and glucagon suppression separately from insulin-mediated glucose uptake
Solution Approach 2:
The peptide compounds serve as intermediary substances that mediate glucose metabolism control through alternative pathways - stimulating insulin secretion in a glucose-dependent manner and suppressing glucagon, thereby achieving glucose control without direct insulin administration and its associated side effects
2Quantity of substance
If long-acting GLP-1 receptor agonists are used to stimulate insulin secretion, then insulin secretion increases in a glucose-dependent manner, but the treatment complexity and cost increase
Solution Approach 1:
The invention changes the molecular parameters by using peptides with specific amino acid sequences (KX2LAX5X6X7X8LX10LX12YGIK and VDZ3Z4Z5GZ7Z8SZ10Z11YGLR) that naturally interact with endogenous receptors, achieving GLP-1-like effects through structurally simpler compounds that may have improved pharmacokinetic properties and reduced treatment complexity
3Object-affected harmful factors
If novel non-insulin compounds are developed to treat diabetes, then associated complications such as weight gain and cancer risk may be reduced, but the effectiveness in addressing insulin resistance and hyperglycemia must be maintained
Solution Approach 1:
The peptide compounds exhibit multi-functionality by simultaneously addressing multiple aspects of diabetes pathology: stimulating β-cell proliferation, protecting against apoptosis, enhancing insulin secretion in a glucose-dependent manner, and suppressing glucagon, thereby controlling hyperglycemia and insulin resistance while avoiding insulin-related side effects
Data Source
Figure 1A~1C
Figure 2A~2B
Figure 3A~3C
AI summary
The present disclosure concerns agents and their use in the treatment of endocrine, nutritional and/or metabolic diseases in a mammal. The disclosure furthermore concerns novel peptides.